Table 1 Clinicopathological characteristics of LIHC patients from the TCGA cohort.
Characteristic | Low expression of BARX2 | High expression of BARX2 | p |
|---|---|---|---|
n | 187 | 187 | Â |
T stage, n (%) | |||
 T1 | 108 (29.1%) | 75 (20.2%) | 0.004 |
 T2 | 36 (9.7%) | 59 (15.9%) | |
 T3 | 34 (9.2%) | 46 (12.4%) | |
 T4 | 7 (1.9%) | 6 (1.6%) | |
Pathologic stage, n (%) | |||
 Stage I | 103 (29.4%) | 70 (20%) | 0.020 |
 Stage II | 36 (10.3%) | 51 (14.6%) | |
 Stage III | 39 (11.1%) | 46 (13.1%) | |
 Stage IV | 2 (0.6%) | 3 (0.9%) | |
Gender, n (%) | |||
 Female | 57 (15.2%) | 64 (17.1%) | 0.507 |
 Male | 130 (34.8%) | 123 (32.9%) | |
Age, n (%) | |||
  <  = 60 | 89 (23.9%) | 88 (23.6%) | 1.000 |
  > 60 | 98 (26.3%) | 98 (26.3%) | |
OS event, n (%) | |||
 Alive | 118 (31.6%) | 126 (33.7%) | 0.447 |
 Dead | 69 (18.4%) | 61 (16.3%) | |
Race, n (%) | |||
 Asian | 83 (22.9%) | 77 (21.3%) | 0.376 |
 Black or African American | 6 (1.7%) | 11 (3%) | |
 White | 88 (24.3%) | 97 (26.8%) | |
Height, n (%) | |||
  < 170 | 108 (31.7%) | 93 (27.3%) | 0.408 |
  >  = 170 | 68 (19.9%) | 72 (21.1%) | |
Histologic grade, n (%) | |||
 G1 | 33 (8.9%) | 22 (6%) | 0.294 |
 G2 | 88 (23.8%) | 90 (24.4%) | |
 G3 | 56 (15.2%) | 68 (18.4%) | |
 G4 | 7 (1.9%) | 5 (1.4%) | |
Residual tumor, n (%) | |||
 R0 | 172 (49.9%) | 155 (44.9%) |  < 0.001 |
 R1 | 2 (0.6%) | 15 (4.3%) | |
 R2 | 1 (0.3%) | 0 (0%) | |
Fibrosis ishak score, n (%) | |||
 0 | 47 (21.9%) | 28 (13%) | 0.395 |
 1/2 | 16 (7.4%) | 15 (7%) | |
 3/4 | 15 (7%) | 13 (6%) | |
 5/6 | 40 (18.6%) | 41 (19.1%) | |
Vascular invasion, n (%) | |||
 No | 115 (36.2%) | 93 (29.2%) | 0.121 |
 Yes | 50 (15.7%) | 60 (18.9%) | |
Age, median (IQR) | 62 (52, 69.5) | 61 (51.25, 68) | 0.539 |
